Find Clinical Trial

Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationAutism Spectrum Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

BUMETANIDE,
S095008

Active Substance CodeS095008
Protocol CodeCL3-95008-002
EudraCT Code2017-004420-30
NCT CodeNCT03715153


Documents and links

Lay summary
Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



More information

https://autism-studies.com

© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility